跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
JCOVDEN SUSPENSION INYECTABLE - CIMA-AEMPS Drug Approval Details
Approvals
/
CIMA-AEMPS
/
JCOVDEN SUSPENSION INYECTABLE
Approved
STANDARD
JCOVDEN SUSPENSION INYECTABLE
Janssen-Cilag International N.V
🇪🇸 Spanish Agency of Medicines and Medical Devices
Approval Date
Mar 15, 2021
Approval ID
8256fae8832b4a47
Company
Janssen-Cilag International N.V
Type
Standard
Approval Details
Approval Id
8256fae8832b4a47
Drug Cima Aemps Name
JCOVDEN SUSPENSION INYECTABLE
Register Number
1201525001
Holder Company Name
Janssen-Cilag International N.V
Marketing Company Name
Janssen Cilag S.A.
Holder Company Detail Path
/organization/janssen-cilag-international-nv
Authorization Date
2021-03-15
Dosage Form
SUSPENSIÓN INYECTABLE
Dose
no menos de 8,92 Log10 U Inf/0,5 ml
Route Of Administration
VÍA INTRAMUSCULAR
Prescription Type
Medicamento Sujeto A Prescripción Médica
Commercialized
No
Company Name
Janssen-Cilag International N.V
Company Detail Path
/organization/janssen-cilag-international-nv
Company Information
Pharmaceutical Company Name
Janssen-Cilag International NV
Country Name
Belgium
Active Ingredients
VACUNA RECOMBINANTE (AD26) FRENTE A COVID-19 (J&J/JANSSEN)
8,92 Log10 unidades infecciosas (Inf.U)
Approved
Quick Info
Agency
CIMA-AEMPS
Country
🇪🇸
Approval Date
Mar 15, 2021
Approval ID
8256fae8832b4a47
Type
Standard
Back to CIMA-AEMPS Approvals